keyword
MENU ▼
Read by QxMD icon Read
search

Novel treatments prostate

keyword
https://www.readbyqxmd.com/read/29150328/randomized-phase-2-therapeutic-equivalence-study-of-abiraterone-acetate-fine-particle-formulation-vs-originator-abiraterone-acetate-in-patients-with-metastatic-castration-resistant-prostate-cancer-the-staar-study
#1
Cy A Stein, Richard Levin, Robert Given, Celestia S Higano, Paul Nemeth, Bill Bosch, Jillian Chapas-Reed, Robert Dreicer
BACKGROUND: This multicenter, randomized, open-label, active-controlled study evaluated therapeutic equivalence, steady-state pharmacokinetics, and safety of a novel abiraterone acetate fine particle formulation (AAFP) 500mg plus methylprednisolone vs. the originator AA (OAA) 1000mg plus prednisone in men with metastatic castrate-resistant prostate cancer (mCRPC). The primary endpoint was a comparison of average of serum testosterone levels on treatment days 9 and 10 between groups. METHODS: Men with progressive mCRPC, receiving gonadotropin-releasing hormone agonist or antagonist therapy, and with a serum testosterone level of <50ng/dl were randomized 1:1 to either AAFP 500mg daily plus 4mg methylprednisolone orally twice daily (BID), or OAA 1000mg daily plus 5mg prednisone BID for 84 days...
November 14, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/29149993/label-free-determination-of-prostate-specific-membrane-antigen-in-human-whole-blood-at-nanomolar-levels-by-magnetically-assisted-surface-enhanced-raman-spectroscopy
#2
Zuzana Chaloupková, Anna Balzerová, Jitka Bařinková, Zdenka Medříková, Pavel Šácha, Petr Beneš, Václav Ranc, Jan Konvalinka, Radek Zbořil
Prostate cancer is one of the most common cancers among men and can in its later stages cause serious medical problems. Due to the limited suitability of current diagnostic biochemical markers, new biomarkers for the detection of prostate cancer are highly sought after. An ideal biomarker should serve as a reliable prognostic marker, be applicable for early diagnosis, and be applicable for monitoring of therapeutic response. One potential candidate is glutamate carboxypeptidase II (GCPII), also known as prostate specific membrane antigen (PSMA), which has a promising role for direct imaging...
January 2, 2018: Analytica Chimica Acta
https://www.readbyqxmd.com/read/29149413/tctp-has-a-crucial-role-in-the-different-stages-of-prostate-cancer-malignant-progression
#3
Virginie Baylot, Sara Karaki, Palma Rocchi
Prostate cancer (PC) is the second most common cause of cancer-related mortality in men in the western world after lung cancer. Many patients are not candidates for resection given the advanced stage of their cancer. The primary treatment for advanced PC is the castration therapy which supresses the production of androgens, hormone that promotes PC growth. Despite the efficiency of the castration therapy, most patients develop castration resistant disease which remains uncurable. Clearly, novel approaches are required to effectively treat castration resistant PC (CRPC)...
2017: Results and Problems in Cell Differentiation
https://www.readbyqxmd.com/read/29147564/a-review-of-orexin-s-unprecedented-potential-as-a-novel-highly-specific-treatment-for-various-localized-and-metastatic-cancers
#4
REVIEW
Nicole L Graybill, Volkmar Weissig
A systematic review was conducted to categorize the types of cancerous tissues that express orexin receptors and also to examine the effect of in vitro administration of orexin A or B to corresponding cell samples. Comprehensive literature analyses of primary experimental studies were performed. The results of the review included an increased frequency of orexin receptor expression in many colon and prostate cancer tissues and an upward trend of pro-apoptotic activity in these aggressive cell types.
2017: SAGE Open Medicine
https://www.readbyqxmd.com/read/29146441/combining-immunotherapies-for-the-treatment-of-prostate-cancer
#5
REVIEW
Jason M Redman, James L Gulley, Ravi A Madan
Sipuleucel-T, a therapeutic dendritic-cell vaccine, was Food and Drug Administration-approved for prostate cancer in 2010. No new immunotherapies for prostate cancer have been approved since. However, novel agents and combination approaches offer great promise for improving outcomes for prostate cancer patients. Here we review the latest developments in immunotherapy for prostate cancer. Sipuleucel-T has demonstrated a survival advantage of 4.1 months in metastatic castration-resistant prostate cancer. PSA-TRICOM (PROSTVAC), a prostate-specific antigen-targeted vaccine platform, showed evidence of clinical and immunologic efficacy in early-phase clinical trials, and results from a phase III trial in advanced disease are pending...
December 2017: Urologic Oncology
https://www.readbyqxmd.com/read/29141691/involvement-of-aberrantly-activated-hotair-ezh2-mir-193a-feedback-loop-in-progression-of-prostate-cancer
#6
Zhixin Ling, Xiaoyan Wang, Tao Tao, Lei Zhang, Han Guan, Zonghao You, Kai Lu, Guangyuan Zhang, Shuqiu Chen, Jianping Wu, Jinke Qian, Hui Liu, Bin Xu, Ming Chen
BACKGROUND: Though androgen deprivation therapy is the standard treatment for prostate cancer (PCa), most patients would inevitably progress to castration-resistant prostate cancer (CRPC) which is the main cause of PCa death. Therefore, the identification of novel molecular mechanism regulating cancer progression and achievement of new insight into target therapy would be necessary for improving the benefits of PCa patients. This study aims to study the function and regulatory mechanism of HOTAIR/EZH2/miR-193a feedback loop in PCa progression...
November 15, 2017: Journal of Experimental & Clinical Cancer Research: CR
https://www.readbyqxmd.com/read/29137633/bi-directional-exosome-driven-intercommunication-between-the-hepatic-niche-and-cancer-cells
#7
Nikolina Dioufa, Amanda M Clark, Bo Ma, Colin H Beckwitt, Alan Wells
BACKGROUND: Our understanding of the multiple roles exosomes play during tumor progression is still very poor and the contribution of the normal tissue derived exosomes in distant seeding and tumor outgrowth has also not been widely appreciated. METHODS: Using our all-human liver microphysiological system (MPS) platform as a model to closely recapitulate the early metastatic events, we isolated exosomes from both tumor cells and liver microenvironment. RESULTS: We observed that while priming of the hepatic niche (HepN) with MDA-231 breast cancer derived exosomes facilitated seeding of the cancer cells in the liver, subsequent tumor outgrowth was diminished; this was consistent with increased entry into dormancy...
November 14, 2017: Molecular Cancer
https://www.readbyqxmd.com/read/29126837/antiandrogens-reduce-intratumoral-androgen-concentrations-and-induce-androgen-receptor-expression-in-castration-resistant-prostate-cancer-xenografts
#8
Matias Knuuttila, Arfa Mehmood, Riikka Huhtaniemi, Emrah Yatkin, Merja R Häkkinen, Riikka Oksala, Teemu D Laajala, Henrik Ryberg, David J Handelsman, Tero Aittokallio, Seppo Auriola, Claes Ohlsson, Asta Laiho, Laura L Elo, Petra Sipilä, Sari I Mäkelä, Matti Poutanen
The development of castration-resistant prostate cancer (CRPC) is associated with the activation of intratumoral androgen biosynthesis and an increase in androgen receptor (AR) expression. We recently demonstrated that similarly to the clinical CRPC, orthotopically grown castration-resistant VCaP (CR-VCaP) xenografts express high levels of AR and retain intratumoral androgen concentrations similar to tumors grown in intact mice. Here, we show that antiandrogen treatment (enzalutamide or ARN-509) significantly reduced (10-fold, P < 0...
November 7, 2017: American Journal of Pathology
https://www.readbyqxmd.com/read/29125921/management-of-anticoagulation-in-patients-with-prostate-cancer-receiving-enzalutamide
#9
Joseph J Shatzel, Molly M Daughety, Sven R Olson, Tomasz M Beer, Thomas G DeLoughery
Enzalutamide, a novel, oral androgen receptor antagonist used for the treatment of metastatic, castration-resistant prostate cancer, has been shown to improve overall and progression-free survival, prolong time to initiation of chemotherapy, reduce skeletal-related events, and carry a favorable adverse effect profile. Metastatic prostate cancer is a disease of older men, a population with an increased incidence of medical comorbidities warranting anticoagulation. Prostate cancer itself, along with some of its therapies, is also prothrombotic...
November 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/29122471/3d-registration-of-mpmri-for-assessment-of-prostate-cancer-focal-therapy
#10
Clément Orczyk, Andrew B Rosenkrantz, Artem Mikheev, Arnauld Villers, Myriam Bernaudin, Samir S Taneja, Samuel Valable, Henry Rusinek
RATIONALE AND OBJECTIVES: This study aimed to assess a novel method of three-dimensional (3D) co-registration of prostate magnetic resonance imaging (MRI) examinations performed before and after prostate cancer focal therapy. MATERIALS AND METHODS: We developed a software platform for automatic 3D deformable co-registration of prostate MRI at different time points and applied this method to 10 patients who underwent focal ablative therapy. MRI examinations were performed preoperatively, as well as 1 week and 6 months post treatment...
November 6, 2017: Academic Radiology
https://www.readbyqxmd.com/read/29119376/regulatory-effects-of-antitumor-agent-matrine-on-foxo-and-pi3k-akt-pathway-in-castration-resistant-prostate-cancer-cells
#11
Qi Li, Hai Huang, Zheng He, Yi Sun, Yufeng Tang, Xiaohong Shang, Chengbin Wang
We previously demonstrated that matrine could inhibit the proliferating, migrating, as well as invading processes of both PC-3 and DU145 cells. However, the underlying molecular mechanisms have not yet been clearly defined. In this study, using various techniques such as high throughput sequencing technology, bioinformatics, quantitative real-time PCR, and immunoblot analysis, we aimed to understand whether matrine serves as a novel regulator of FOXO and PI3K-AKT signaling pathway. DU145 and PC-3 cell lines were cultured for 24 h in vitro...
November 7, 2017: Science China. Life Sciences
https://www.readbyqxmd.com/read/29116202/acetylated-histone-variant-h2a-z-is-involved-in-the-activation-of-neo-enhancers-in-prostate-cancer
#12
Fátima Valdés-Mora, Cathryn M Gould, Yolanda Colino-Sanguino, Wenjia Qu, Jenny Z Song, Kylie M Taylor, Fabian A Buske, Aaron L Statham, Shalima S Nair, Nicola J Armstrong, James G Kench, Kenneth M L Lee, Lisa G Horvath, Minru Qiu, Alexei Ilinykh, Nicole S Yeo-Teh, David Gallego-Ortega, Clare Stirzaker, Susan J Clark
Acetylation of the histone variant H2A.Z (H2A.Zac) occurs at active promoters and is associated with oncogene activation in prostate cancer, but its role in enhancer function is still poorly understood. Here we show that H2A.Zac containing nucleosomes are commonly redistributed to neo-enhancers in cancer resulting in a concomitant gain of chromatin accessibility and ectopic gene expression. Notably incorporation of acetylated H2A.Z nucleosomes is a pre-requisite for activation of Androgen receptor (AR) associated enhancers...
November 7, 2017: Nature Communications
https://www.readbyqxmd.com/read/29110617/degradation-of-androgen-receptor-through-small-molecules-for-prostate-cancer
#13
Raoling Ge, Xi Xu, Pengfei Xu, Lei Li, Zhiyu Li, Jinlei Bian
Prostate cancer is the most common carcinoma among aged males in western countries and more aggressive and lethal castration resistant prostate cancer often occurs after androgen deprivation therapy. The high expression of androgens and androgen receptor is closely related to prostate cancer. Efficient androgen receptor antagonists, such as enzalutamide and ARN-509, could be employed as potent anti-prostate cancer agents. Nevertheless, recent studies have revealed that F876L mutation in androgen receptor converts the action of enzalutamide and ARN-509 from an antagonist to agonist, so that novel strategies are urgent to address this resistance mechanism...
November 6, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/29110173/combination-treatment-with-docetaxel-and-histone-deacetylase-inhibitors-downregulates-androgen-receptor-signaling-in-castration-resistant-prostate-cancer
#14
Sang Eun Park, Ha-Gyeong Kim, Dong Eun Kim, Yoo Jung Jung, Yunlim Kim, Seong-Yun Jeong, Eun Kyung Choi, Jung Jin Hwang, Choung-Soo Kim
Backgrounds Since most patients with castration-resistant prostate cancer (CRPC) develop resistance to its standard therapy docetaxel, many studies have attempted to identify novel combination treatment to meet the large clinical unmet need. In this study, we examined whether histone deacetylase inhibitors (HDACIs) enhanced the effect of docetaxel on AR signaling in CRPC cells harboring AR and its splice variants. Methods HDACIs (vorinostat and CG200745) were tested for their ability to enhance the effects of docetaxel on cell viability and inhibition of AR signaling in CRPC 22Rv1 and VCaP cells by using CellTiter-Glo™ Luminescent cell viability assay, synergy index analysis and Western blotting...
November 7, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/29108267/beta-catenin-represses-protein-kinase-d1-gene-expression-by-non-canonical-pathway-through-myc-max-transcription-complex-in-prostate-cancer
#15
Bita Nickkholgh, Sivanandane Sittadjody, Michael B Rothberg, Xiaolan Fang, Kunzhao Li, Jeff W Chou, Gregory A Hawkins, K C Balaji
Down regulation of Protein Kinase D1 (PrKD1), a novel serine threonine kinase, in prostate, gastric, breast and colon cancers in humans leads to disease progression. While the down regulation of PrKD1 by DNA methylation in gastric cancer and by nuclear beta-catenin in colon cancer has been shown, the regulatory mechanisms in other cancers are unknown. Because we had demonstrated that PrKD1 is the only known kinase to phosphorylate threonine 120 (T120) of beta-catenin in prostate cancer resulting in increased nuclear beta-catenin, we explored the role of beta-catenin in gene regulation of PrKD1...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29108245/reversion-of-epithelial-mesenchymal-transition-by-a-novel-agent-dz-50-via-igf-binding-protein-3-in-prostate-cancer-cells
#16
Zheng Cao, Shahriar Koochekpour, Stephen E Strup, Natasha Kyprianou
Dysregulation of transforming growth factor-β1 (TGF-β1) and insulin-like growth factor (IGF) axis has been linked to reactive stroma dynamics in prostate cancer progression. IGF binding protein-3 (IGFBP3) induction is initiated by stroma remodeling and could represent a potential therapeutic target for prostate cancer. In previous studies a lead quinazoline-based Doxazosin® derivative, DZ-50, impaired prostate tumor growth by targeting proteins involved in focal adhesion, anoikis resistance and epithelial-mesenchymal-transition (EMT)...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29105802/circulating-micrornas-and-treatment-response-in-the-phase-ii-swog-s0925-study-for-patients-with-new-metastatic-hormone-sensitive-prostate-cancer
#17
Heather H Cheng, Melissa Plets, Hongli Li, Celestia S Higano, Catherine M Tangen, Neeraj Agarwal, Nicholas J Vogelzang, Maha Hussain, Ian M Thompson, Muneesh Tewari, Evan Y Yu
BACKGROUND: Previous studies suggest circulating, blood-based microRNAs (miRNAs) may serve as minimally invasive prostate cancer biomarkers, however there is limited data from prospective clinical trials. Here, we explore the role of candidate plasma miRNAs as potential biomarkers in the SWOG 0925 randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer. METHODS: Correlative biospecimens, including circulating tumor cells (CTCs) and plasma for miRNA analysis, were collected at baseline and after 12 weeks on treatment from 50 patients enrolled on SWOG 0925...
November 6, 2017: Prostate
https://www.readbyqxmd.com/read/29105797/-99m-tc-mip-1404-spect-ct-for-the-detection-of-psma-positive-lesions-in-225-patients-with-biochemical-recurrence-of-prostate-cancer
#18
Christian Schmidkonz, Claudia Hollweg, Michael Beck, Julia Reinfelder, Theresa I Goetz, James C Sanders, Daniela Schmidt, Olaf Prante, Tobias Bäuerle, Alexander Cavallaro, Michael Uder, Bernd Wullich, Peter Goebell, Torsten Kuwert, Philipp Ritt
BACKGROUND: (99m) Tc-MIP-1404 (Progenics Pharmaceuticals, Inc., New York, NY) is a novel, SPECT-compatible (99m) Tc-labeled PSMA inhibitor for the detection of prostate cancer. We present results of its clinical use in a cohort of 225 men with histologically confirmed prostate cancer referred for workup of biochemical relapse. METHODS: From April 2013 to April 2017, (99m) Tc-MIP1404-scintigraphy was performed in 225 patients for workup of PSA biochemical relapse of prostate cancer...
November 6, 2017: Prostate
https://www.readbyqxmd.com/read/29104741/lymph-node-imaging-in-initial-staging-of-prostate-cancer-an-overview-and-update
#19
REVIEW
Jessica G Zarzour, Sam Galgano, Jonathan McConathy, John V Thomas, Soroush Rais-Bahrami
Accurate nodal staging at the time of diagnosis of prostate cancer is crucial in determining a treatment plan for the patient. Pelvic lymph node dissection is the most reliable method, but is less than perfect and has increased morbidity. Cross sectional imaging with computed tomography (CT) and magnetic resonance imaging (MRI) are non-invasive tools that rely on morphologic characteristics such as shape and size of the lymph nodes. However, lymph nodes harboring metastatic disease may be normal sized and non-metastatic lymph nodes may be enlarged due to reactive hyperplasia...
October 28, 2017: World Journal of Radiology
https://www.readbyqxmd.com/read/29102858/weekly-cabazitaxel-plus-prednisone-is-effective-and-less-toxic-for-unfit-metastatic-castration-resistant-prostate-cancer-phase-ii-spanish-oncology-genitourinary-group-sogug-trial
#20
Miguel Ángel Climent, Begoña Pérez-Valderrama, Begoña Mellado, Eva María Fernández Parra, Ovidio Fernández Calvo, María Ochoa de Olza, Laura Muinelo Romay, Urbano Anido, Montserrat Domenech, Susana Hernando Polo, José Ángel Arranz Arija, Cristina Caballero, María José Juan Fita, Daniel Castellano
AIM: Cabazitaxel (CBZ), a novel tubulin-binding taxane, improves overall survival in metastatic castration-resistant prostate cancer (mCRPC) that progresses during or after docetaxel treatment. We have designed a phase II study to evaluate the efficacy and safety of CBZ as a weekly schedule for 'unfit' mCRPC patients after docetaxel failure. METHODS: In this single arm phase II study. CBZ was weekly administered in 1-hour infusion on days 1, 8, 15 and 22, every 5 weeks at 10 mg/m(2) to eligible 'unfit' patients; oral prednisone (5 mg) was administered twice a day...
November 2, 2017: European Journal of Cancer
keyword
keyword
110082
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"